| Literature DB >> 32615958 |
Laleh Ebrahimi Ghahnavieh1, Hossein Tabatabaeian2,3, Zhaleh Ebrahimi Ghahnavieh4, Mohammad Amin Honardoost5, Mansoureh Azadeh6, Mohamad Moazeni Bistgani7, Kamran Ghaedi8,9.
Abstract
BACKGROUND: Gastric cancer is the fifth most common cancer worldwide. Along with environmental factors, such as Helicobacter pylori (H. pylori) infection, genetic changes play important roles in gastric tumor formations. miR-584 is a less well-characterized microRNA (miRNA), with apparent activity in human cancers. However, miR-584 expression pattern in gastric cancer development has remained unclear. This study aims to analyze the expression of miR-584 in gastric cancer samples and investigates the associations between this miRNA and H. pylori infection and clinical characteristics.Entities:
Keywords: Computational analysis; Gastric cancer; Helicobacter pylori; miR-584
Year: 2020 PMID: 32615958 PMCID: PMC7345521 DOI: 10.1186/s12885-020-07116-5
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Patient sample characteristics
| Variable | Control ( | Case ( | ||
|---|---|---|---|---|
| 49.73 (21.45) | 61.13 (13.54) | 0.055 * | ||
| 4 | 6 | 0.406 ** | ||
| 7 | 20 | |||
| 5 | 12 | 0.969 ** | ||
| 6 | 14 | |||
SD Standard deviation, H. pylori Helicobacter pylori
* Independent t-test
** Chi-square test
Fig. 1a Analysis of miR-584 expression in the patient’s tumor versus normal tissue. b In silico analysis of miR-584 in paired TCGA clinical gastric cancer and normal gastric mucosa samples. c In silico analysis of miR-584 in unpaired TCGA clinical gastric cancer samples. d Analysis of SH3TC2 expression in the patient’s tumor versus normal tissue. e Correlation between miR-584 and SH3TC2 expression gastric cancer samples. *** P < 0.005
Fig. 2a Analysis of miR-584 expression in four H. pylori-categorized normal and tumor samples. b Analysis of miR-584 expression in H. pylori-positive and negative samples. c Analysis of miR-584 expression in H. pylori-categorized TCGA clinical samples. * P < 0.05, ** P < 0.01, *** P < 0.005
Fig. 3a Analysis of miR-584 in different gastric cancer stages. b Correlation of miR-584 and different stages of gastric cancer samples. c Analysis of miR-584 expression in different gastric cancer stages of TCGA gastric cancer samples. d Analysis of miR-584 in lymph node-negative and positive gastric tumors. e Analysis of miR-584 among tumors with different regional lymph node involvement. f Analysis of miR-584 expression among gastric tumors with different depths of invasion. * P < 0.05, ** P < 0.01
Fig. 4a Survival analysis of miR-584 expression in four different gastric tumor stages. b In silico survival analysis of miR-584 expression in clinical gastric cancer subjects. c In silico survival analysis of miR-584 expression in patients with stage IV of gastric cancer. d Proposed schematic of miR-584 expression pattern in gastric cancer development
Top statistically related signaling pathways to miR-584 targetome obtained from KEGG database through DAVID tool
| Rank | KEGG Pathway | Number of genes (%) | |
|---|---|---|---|
| 1 | Pathways in cancer | 21 (2.9) | 5.4E2 |
| 2 | Regulation of actin cytoskeleton | 19 (2.6) | 3.4E3 |
| 3 | Focal adhesion | 17 (2.4) | 9.1E3 |
| 4 | Ubiquitin mediated proteolysis | 15 (2.1) | 1.6E3 |
| 5 | Chemokine signaling pathway | 14 (1.9) | 4.7E2 |
| 6 | Endocytosis | 13 (1.8) | 8.1E2 |
| 7 | Fc gamma Rmediated phagocytosis | 12 () | 1.8E3 |
| 8 | Chronic myeloid leukemia | 11 (1.7) | 9.9E4 |
| 9 | Insulin signaling pathway | 11 (1.5) | 5.4E2 |
| 10 | Wnt signaling pathway | 11 (1.5) | 9.8E2 |
| 11 | Pancreatic cancer | 10 (1.4) | 2.8E3 |
| 12 | Adherens junction | 10 (1.4) | 4.4E3 |
| 13 | Vascular smooth muscle contraction | 9 (1.2) | 9.4E2 |
| 14 | Colorectal cancer | 9 (1.2) | 2.3E2 |
| 15 | TGFbeta signaling pathway | 9 (1.2) | 2.8E2 |
| 16 | Oocyte meiosis | 9 (1.2) | 8.7E2 |
| 17 | Longterm potentiation | 8 (1.1) | 2.2E2 |
| 18 | Phosphatidylinositol signaling system | 8 (1.1) | 3.4E2 |
| 19 | Endometrial cancer | 7 (1) | 2.0E2 |
| 20 | Acute myeloid leukemia | 7 (1) | 3.3E2 |
| 21 | Melanoma | 7 (1) | 7.4E2 |
| 22 | B cell receptor signaling pathway | 7 (1) | 9.1E2 |
| 23 | VEGF signaling pathway | 7 (1) | 9.1E2 |
| 24 | Nonsmall cell lung cancer | 6 (0.8) | 7.3E2 |
| 25 | Dorsoventral axis formation | 4 (0.6) | 8.4E2 |
* The threshold of EASE score, a modified Fisher Exact P-value, for gene-enrichment analysis
Fig. 5In silico correlation of miR-584 and (a) STAT1, (b) CCND1, (c) PIK3CA and (d) PTEN expression levels in TCGA samples. e Correlation of miR-584 and STAT1 expression levels in 5 normal gastric mocusa and 10 gastric cancer clinical samples